Premature Labor (Tocolysis) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Premature Labor (Tocolysis) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H2 2014', provides an overview of the Premature Labor (Tocolysis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Premature Labor (Tocolysis) Overview 7
Therapeutics Development 8
Pipeline Products for Premature Labor (Tocolysis) - Overview 8
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 9
Premature Labor (Tocolysis) - Therapeutics under Development by Companies 10
Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes 11
Premature Labor (Tocolysis) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Premature Labor (Tocolysis) - Products under Development by Companies 15
Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes 16
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 17
GlaxoSmithKline plc 17
Actavis plc 18
Kissei Pharmaceutical Co., Ltd. 19
PDC Biotech GmbH 20
ObsEva SA 21
Premature Labor (Tocolysis) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
retosiban - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
bedoradrine sulfate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PDC-31 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Progesterone Vaginal Gel Second Generation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OBE-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Progesterone Based Formulation For Preterm Birth - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OBE-002 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AT-814 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drug for Postpartum Depression and Premature Labor - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Premature Labor (Tocolysis) - Recent Pipeline Updates 42
Premature Labor (Tocolysis) - Dormant Projects 44
Premature Labor (Tocolysis) - Discontinued Products 45
Premature Labor (Tocolysis) - Product Development Milestones 46
Featured News & Press Releases 46
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor 46
Oct 17, 2012: Progesterone Drug Fails To Prevent Preterm Birth In High Risk Group, NIH Study Shows 46
Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8% 47
Feb 09, 2012: Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories 48
Jan 20, 2012: FDA Advisory Committee Declines To Recommend Approval Of Watson's Progesterone Vaginal Gel 8% For Reduction Of Risk Of Preterm Birth In Women With Short Uterine Cervical Length 48
Nov 10, 2011: Columbia Laboratories And Watson Pharmaceuticals Confirm FDA Advisory Committee To Review Preterm Birth NDA 49
Jun 27, 2011: Columbia Laboratories' NDA For PROCHIEVE Vaginal Progesterone Gel Accepted For Filing By FDA 49
Apr 26, 2011: Columbia Laboratories Submits NDA For PROCHIEVE Vaginal Progesterone Gel 50
Apr 06, 2011: NIH Study Finds Progesterone Reduces Rate Of Early Preterm Birth In At Risk Women 50
Apr 06, 2011: Columbia And Watson Announce Publication Of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H2 2014 8
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Comparative Analysis by Unknown Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H2 2014 17
Premature Labor (Tocolysis) - Pipeline by Actavis plc, H2 2014 18
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 19
Premature Labor (Tocolysis) - Pipeline by PDC Biotech GmbH, H2 2014 20
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H2 2014 42
Premature Labor (Tocolysis) - Dormant Projects, H2 2014 44
Premature Labor (Tocolysis) - Discontinued Products, H2 2014 45